181 related articles for article (PubMed ID: 32246995)
1. Mixed fungaemia: an 18-year report from a tertiary-care university hospital and a systematic review.
Gülmez D; Alp S; Gursoy G; Ayaz CM; Dogan O; Arikan-Akdagli S; Akova M
Clin Microbiol Infect; 2020 Jul; 26(7):833-841. PubMed ID: 32246995
[TBL] [Abstract][Full Text] [Related]
2. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
3. Fungaemia due to rare yeasts in a tertiary care university centre within 18 years.
Alp S; Gulmez D; Ayaz CM; Arikan-Akdagli S; Akova M
Mycoses; 2020 May; 63(5):488-493. PubMed ID: 32145101
[TBL] [Abstract][Full Text] [Related]
4. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.
Tumbarello M; Sanguinetti M; Trecarichi EM; La Sorda M; Rossi M; de Carolis E; de Gaetano Donati K; Fadda G; Cauda R; Posteraro B
J Antimicrob Chemother; 2008 Dec; 62(6):1379-85. PubMed ID: 18782778
[TBL] [Abstract][Full Text] [Related]
5. Candida glabrata fungaemia in a tertiary centre in Taiwan: antifungal susceptibility and outcomes.
Ruan SY; Huang YT; Chu CC; Yu CJ; Hsueh PR
Int J Antimicrob Agents; 2009 Sep; 34(3):236-9. PubMed ID: 19361960
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey.
Pemán J; Cantón E; Quindós G; Eraso E; Alcoba J; Guinea J; Merino P; Ruiz-Pérez-de-Pipaon MT; Pérez-del-Molino L; Linares-Sicilia MJ; Marco F; García J; Roselló EM; Gómez-G-de-la-Pedrosa E; Borrell N; Porras A; Yagüe G;
J Antimicrob Chemother; 2012 May; 67(5):1181-7. PubMed ID: 22351683
[TBL] [Abstract][Full Text] [Related]
7. Candida glabrata fungaemia in intensive care units.
Ruan SY; Lee LN; Jerng JS; Yu CJ; Hsueh PR
Clin Microbiol Infect; 2008 Feb; 14(2):136-40. PubMed ID: 18042196
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital.
Bedini A; Venturelli C; Mussini C; Guaraldi G; Codeluppi M; Borghi V; Rumpianesi F; Barchiesi F; Esposito R
Clin Microbiol Infect; 2006 Jan; 12(1):75-80. PubMed ID: 16460550
[TBL] [Abstract][Full Text] [Related]
9. Antifungal susceptibility of 262 bloodstream yeast isolates from a mixed cancer and non-cancer patient population: is there a correlation between in-vitro resistance to fluconazole and the outcome of fungemia?
Kovacicova G; Krupova Y; Lovaszova M; Roidova A; Trupl J; Liskova A; Hanzen J; Milosovic P; Lamosova M; Macekova L; Szovenyiova Z; Purgelova A; Obertik T; Bille J; Krcmery V
J Infect Chemother; 2000 Dec; 6(4):216-21. PubMed ID: 11810569
[TBL] [Abstract][Full Text] [Related]
10. Comparison of fungemia caused by Candida and non-Candida rare yeasts: a retrospective study from a tertiary care hospital.
Oz Y; Yılmaz M; Bulduk T; Basayigit M; Gunduz E; Metintas S
Med Mycol; 2024 May; 62(5):. PubMed ID: 38627248
[TBL] [Abstract][Full Text] [Related]
11. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
Jensen RH
Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
[TBL] [Abstract][Full Text] [Related]
12. A retrospective analysis of antifungal susceptibilities of Candida bloodstream isolates from Singapore hospitals.
Tan TY; Tan AL; Tee NW; Ng LS
Ann Acad Med Singap; 2008 Oct; 37(10):835-40. PubMed ID: 19037517
[TBL] [Abstract][Full Text] [Related]
13. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme.
Arendrup MC; Dzajic E; Jensen RH; Johansen HK; Kjaeldgaard P; Knudsen JD; Kristensen L; Leitz C; Lemming LE; Nielsen L; Olesen B; Rosenvinge FS; Røder BL; Schønheyder HC
Clin Microbiol Infect; 2013 Aug; 19(8):E343-53. PubMed ID: 23607326
[TBL] [Abstract][Full Text] [Related]
14. [Multicenter study of fungemia due to yeasts in Argentina].
Rodero L; Davel G; Soria M; Vivot W; Córdoba S; Canteros CE; Saporiti A;
Rev Argent Microbiol; 2005; 37(4):189-95. PubMed ID: 16502638
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics of Candida tropicalis fungaemia with reduced triazole susceptibility in Taiwan: a multicentre study.
Liu WL; Huang YT; Hsieh MH; Hii IM; Lee YL; Ho MW; Liu CE; Chen YH; Wang FD
Int J Antimicrob Agents; 2019 Feb; 53(2):185-189. PubMed ID: 30722962
[TBL] [Abstract][Full Text] [Related]
16. Monitoring the Epidemiology and Antifungal Resistance of Yeasts Causing Fungemia in a Tertiary Care Hospital in Madrid, Spain: Any Relevant Changes in the Last 13 Years?
Díaz-García J; Mesquida A; Sánchez-Carrillo C; Reigadas E; Muñoz P; Escribano P; Guinea J
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33468487
[TBL] [Abstract][Full Text] [Related]
17. A first Portuguese epidemiological survey of fungaemia in a university hospital.
Costa-de-Oliveira S; Pina-Vaz C; Mendonça D; Gonçalves Rodrigues A
Eur J Clin Microbiol Infect Dis; 2008 May; 27(5):365-74. PubMed ID: 18204871
[TBL] [Abstract][Full Text] [Related]
18. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
Karabıçak N; Alem N
Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
[TBL] [Abstract][Full Text] [Related]
19. Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital.
Posteraro B; Spanu T; Fiori B; De Maio F; De Carolis E; Giaquinto A; Prete V; De Angelis G; Torelli R; D'Inzeo T; Vella A; De Luca A; Tumbarello M; Ricciardi W; Sanguinetti M
Antimicrob Agents Chemother; 2015 Jul; 59(7):3944-55. PubMed ID: 25896705
[TBL] [Abstract][Full Text] [Related]
20. Predisposing factors and outcome of uncommon yeast species-related fungaemia based on an exhaustive surveillance programme (2002-14).
Bretagne S; Renaudat C; Desnos-Ollivier M; Sitbon K; Lortholary O; Dromer F;
J Antimicrob Chemother; 2017 Jun; 72(6):1784-1793. PubMed ID: 28333259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
